DEEP MEDICINE ACQUISITI-CL A (DMAQ) Fundamental Analysis & Valuation

NASDAQ:DMAQ • US2437331026

2.96 USD
-5.43 (-64.72%)
At close: Jan 31, 2024
2.98 USD
+0.02 (+0.68%)
After Hours: 1/31/2024, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DMAQ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Overall DMAQ gets a fundamental rating of 1 out of 10. We evaluated DMAQ against 0 industry peers in the Unkown industry. While DMAQ seems to be doing ok healthwise, there are quite some concerns on its profitability. DMAQ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. DMAQ Profitability Analysis

1.1 Basic Checks

  • DMAQ had negative earnings in the past year.
  • DMAQ had a negative operating cash flow in the past year.
DMAQ Yearly Net Income VS EBIT VS OCF VS FCFDMAQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -500K -1M -1.5M -2M

1.2 Ratios

Industry RankSector Rank
ROA -5.1%
ROE -22.17%
ROIC N/A
ROA(3y)-5.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMAQ Yearly ROA, ROE, ROICDMAQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -5 -10 -15 -20

1.3 Margins

  • DMAQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAQ Yearly Profit, Operating, Gross MarginsDMAQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DMAQ Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for DMAQ has been reduced compared to 1 year ago.
  • DMAQ has a worse debt/assets ratio than last year.
DMAQ Yearly Shares OutstandingDMAQ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M
DMAQ Yearly Total Debt VS Total AssetsDMAQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • DMAQ has an Altman-Z score of 0.08. This is a bad value and indicates that DMAQ is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for DMAQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACCN/A
DMAQ Yearly LT Debt VS Equity VS FCFDMAQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 3.03 indicates that DMAQ has no problem at all paying its short term obligations.
  • DMAQ has a Quick Ratio of 3.03. This indicates that DMAQ is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 3.03
DMAQ Yearly Current Assets VS Current LiabilitesDMAQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DMAQ Growth Analysis

3.1 Past

  • DMAQ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -466.67%.
EPS 1Y (TTM)-466.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. DMAQ Valuation Analysis

4.1 Price/Earnings Ratio

  • DMAQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAQ Price Earnings VS Forward Price EarningsDMAQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAQ Per share dataDMAQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DMAQ Dividend Analysis

5.1 Amount

  • DMAQ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

DMAQ Fundamentals: All Metrics, Ratios and Statistics

DEEP MEDICINE ACQUISITI-CL A

NASDAQ:DMAQ (1/31/2024, 8:00:01 PM)

After market: 2.98 +0.02 (+0.68%)

2.96

-5.43 (-64.72%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners7.28%
Inst Owner Change0%
Ins Owners65.87%
Ins Owner Change0%
Market Cap12.91M
Revenue(TTM)N/A
Net Income(TTM)-510.00K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.61
P/tB 5.61
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.1%
ROE -22.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.03
Quick Ratio 3.03
Altman-Z 0.08
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-466.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-238.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.57%
OCF growth 3YN/A
OCF growth 5YN/A

DEEP MEDICINE ACQUISITI-CL A / DMAQ FAQ

What is the ChartMill fundamental rating of DEEP MEDICINE ACQUISITI-CL A (DMAQ) stock?

ChartMill assigns a fundamental rating of 1 / 10 to DMAQ.


What is the valuation status for DMAQ stock?

ChartMill assigns a valuation rating of 0 / 10 to DEEP MEDICINE ACQUISITI-CL A (DMAQ). This can be considered as Overvalued.


How profitable is DEEP MEDICINE ACQUISITI-CL A (DMAQ) stock?

DEEP MEDICINE ACQUISITI-CL A (DMAQ) has a profitability rating of 0 / 10.


Can you provide the financial health for DMAQ stock?

The financial health rating of DEEP MEDICINE ACQUISITI-CL A (DMAQ) is 5 / 10.